Literature DB >> 6213074

Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction.

B M Frey, F J Frey, N H Holford, F Lozada, L Z Benet.   

Abstract

Eight to 14 plasma samples were obtained from 12 patients on chronic prednisone treatment following their usual dose of prednisone (0.262 to 1.053 mg/kg . day) and following an equivalent amount of prednisolone given i.v. Total and unbound prednisolone were assessed by high performance liquid chromatography and by equilibrium dialysis. The immunosuppressive activity of the plasma was determined as the inhibition of the mixed lymphocyte reaction. The area under the plasma concentration time curve (AUC) for total and unbound prednisolone and the area under the inhibition time curve (AUIC) of the mixed lymphocyte reaction were determined by the trapezoidal rule. A hyperbolic concentration response curve was found when inhibition of the mixed lymphocyte reaction was plotted versus concentrations of total and free prednisolone. The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml. A similar hyperbolic relationship is observed when the AUIC is plotted versus the AUC of free or total prednisolone, but not when AUIC is plotted versus the oral dose. Over the range of drug concentrations observed, no difference is found between total and free concentrations in the ability to predict inhibition of the mixed lymphocyte reaction.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213074     DOI: 10.1097/00007890-198206000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  12 in total

1.  Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models", Clin Pharmacokin 6:429-453 (1981)-The Backstory.

Authors:  Nick Holford
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

2.  Role of altered prednisolone-specific lymphocyte sensitivity in chronic renal failure as a pharmacodynamic marker of acute allograft rejection after kidney transplantation.

Authors:  X X Kang; T Hirano; K Oka; E Sakurai; T Tamaki; M Kozaki
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

Authors:  F J Frey; M K Rüegsegger; B M Frey
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 5.  Immunosuppressive therapy for renal transplantation.

Authors:  C B Carpenter; T B Strom
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Steroids and modern immunosuppression.

Authors:  J R Salaman
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

7.  Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation.

Authors:  L Ost; I Björkhem; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin.

Authors:  J F Flaherty; S L Barriere; J Mordenti; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

9.  Depletion of lymphocytes with membrane markers of helper phenotype: a feature of acute and chronic drug-induced immunosuppression.

Authors:  E Dupont; L Schandene; R Devos; M Lambermont; J Wybran
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

10.  Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.

Authors:  N Holford; Y Hashimoto; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.